- Home
- FCCO vs NERV Comparison
FCCO vs NERV Comparison
Compare FCCO & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FCCO | NERV |
|---|---|---|
| Founded | 1994 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.0M | 207.7M |
| IPO Year | 1998 | 2014 |
Fundamental Metrics
Financial Performance| Metric | FCCO | NERV |
|---|---|---|
| Price | $29.80 | $6.29 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 85.9K | ★ 101.4K |
| Earning Date | 01-28-2026 | 02-23-2026 |
| Dividend Yield | ★ 2.14% | N/A |
| EPS Growth | ★ 36.46 | N/A |
| EPS | ★ 2.47 | N/A |
| Revenue | ★ $78,007,000.00 | N/A |
| Revenue This Year | $30.67 | N/A |
| Revenue Next Year | $5.87 | N/A |
| P/E Ratio | $12.13 | ★ N/A |
| Revenue Growth | ★ 19.77 | N/A |
| 52 Week Low | $19.46 | $1.15 |
| 52 Week High | $31.50 | $12.46 |
Technical Indicators
Market Signals| Indicator | FCCO | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 49.94 | 71.96 |
| Support Level | $30.61 | $4.13 |
| Resistance Level | $31.43 | $6.47 |
| Average True Range (ATR) | 0.75 | 0.55 |
| MACD | 0.03 | 0.22 |
| Stochastic Oscillator | 55.15 | 93.00 |
Price Performance
Historical ComparisonAbout FCCO First Community Corporation
First Community Corp is a bank holding company. Along with its subsidiaries, it provides various banking products and services for professionals and small and medium-sized businesses, including consumer and commercial banking, mortgage, brokerage and investment, online banking, and insurance services. The company offers checking, savings, money market, individual retirement, and certificates of deposit accounts, and its lending lines include consumer loans, real estate loans, home improvement loans, home loans, flex loans, construction loans, agricultural loans, and others. The company's reportable segments are; Commercial and Retail Banking, which derives maximum revenue; Mortgage Banking; Investment Advisory and Non-Deposit; and Corporate.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.